The pharmaceutical industry waited many years for the finalisation and publication of Annex 1 of the EU GMP Guidelines, which was released at the end of August 2022. Anticipation surrounding the document was considerable, and it is now evident that Annex 1 has become an internationally accepted regulatory standard.
The guideline provides overarching principles for the design, operation, and control of facilities, equipment, systems, and procedures used in the manufacture of sterile medicinal products.
CCS and QRM are noted as key drivers in Annex 1. A consistent requirement for a CCS, together with the systematic application of Quality Risk Management (QRM), runs throughout the entire document. Within this framework, the CCS is defined as an integrated, end-to-end approach to sterile pharmaceutical manufacturing, detailing the measures necessary to reduce the risk of microbial, particulate, and pyrogenic contamination.
Prior to the implementation of the revised Annex 1, risk assessments were already commonly performed for most manufacturing steps. Tools such as Failure Mode and Effects Analysis (FMEA) were used to identify potential contamination sources and to define suitable mitigation actions. Manufacturing processes were subdivided into individual steps, each assessed for contamination hazards and evaluated to determine whether appropriate controls existed or needed to be introduced. It should also be noted that, from a regulatory standpoint, quality control activities are considered part of the manufacturing process. Consequently, the EU GMP Guidelines, including Annex 1, apply equally to quality control operations.
Isolators differ fundamentally from RABS by providing a fully closed and rigid physical separation
Isolator technology fully aligned with current regulatory expectations
Over the past two decades, isolator systems have firmly established themselves within the pharmaceutical industry as a proven technology for both sterile manufacturing and quality control. Annex 1 explicitly acknowledges this development in several sections and provides a clear recommendation for the use of barrier technologies, as they substantially enhance product protection against contamination risks arising from endotoxins/pyrogens, particles, and microorganisms introduced by personnel, materials, or the surrounding environment.
Preventing operator involvement in critical aseptic steps is recognised as a crucial measure for contamination prevention. For this reason, Annex 1 explicitly identifies
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cleanroom Technology.
Subscribe now Already a subscriber? Sign in here.